Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03353415
Other study ID # 2017-27
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 7, 2019
Est. completion date April 12, 2023

Study information

Verified date August 2023
Source Joslin Diabetes Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if the use of a continuous glucose monitor (CGM) by people who experience low blood sugars (hypoglycemia) after gastric surgery can help reduce the number and severity of low blood sugar episodes.


Description:

The CGM devices used in this study are approved by the Food and Drug Administration (FDA) for monitoring the glucose levels of people with diabetes. The investigators of this study are looking to see if these CGM devices are able to benefit people who have had gastric surgery and experience low blood sugar episodes, which can be asymptomatic and lead to complications, impairing safety. This study involves wearing a CGM sensor/transmitter during first a masked phase (unable to see CGM sensor glucose levels), followed by an unmasked phase (able to see and respond to sensor glucose levels and alarms). Participants are asked to regularly record fingerstick (capillary) blood sugar values and any symptoms experienced, as well as a record of treatments for symptoms and glucose levels. Participants attend three to five study visits: 5 visits for participants who wore the Dexcom G4, and 3 visits for participants who wore the Dexcom G6. The Dexcom G4 became unavailable during the course of the study when the G6 was introduced. (The Dexcom G4 had a 7 day wear period versus a 10 day wear period for the G6. As the G6 has a longer wear period, the frequency of the study visits was able to be decreased). This study also involves the use of a fitness tracker, which will be worn for the duration of the study and returned at the end of the study. Participants wearing the Dexcom G4 device were able to keep the Dexcom G4 CGM receiver and transmitter (this was not possible with the Dexcom G6 system).


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date April 12, 2023
Est. primary completion date November 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Males or females diagnosed with ongoing post-bariatric or post-gastric surgery hypoglycemia with prior episodes of neuroglycopenia 2. Age 18-65 years of age, inclusive, at screening 3. Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits. Exclusion Criteria: 1. Documented hypoglycemia occurring in the fasting state (> 12 hours fast); 2. Chronic kidney disease stage 4 or 5 (including end-stage renal disease); 3. Hepatic disease, including serum alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin >2.0; 4. Congestive heart failure, New York Heart Association (NYHA) class II, Ill or IV; 5. History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use. 6. History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia 7. Concurrent administration of beta-blocker therapy; 8. History of a cerebrovascular accident; 9. Seizure disorder (other than with suspect or documented hypoglycemia); 10. Active treatment with any diabetes medications except for acarbose; 11. Active treatment with octreotide or diazoxide; 12. Active malignancy, except basal cell or squamous cell skin cancers; 13. Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia (MEN) 2, neurofibromatosis, or Von Hippel-Lindau disease); 14. Known insulinoma; 15. Major surgical operation within 30 days prior to screening; 16. Hematocrit< 33%; 17. Bleeding disorder, treatment with warfarin, or platelet count <50,000; 18. Blood donation (1 pint of whole blood) within the past 2 months; 19. Active alcohol abuse or substance abuse; 20. Current administration of oral or parenteral corticosteroids; 21. Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill/patch I vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. 22. Use of an investigational drug within 30 days prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Dexcom CGM masked
The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)). The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).
Dexcom CGM unmasked
During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop. The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).

Locations

Country Name City State
United States Joslin Diabetes Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Joslin Diabetes Center DexCom, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cummings C, Jiang A, Sheehan A, Ferraz-Bannitz R, Puleio A, Simonson DC, Dreyfuss JM, Patti ME. Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability. Diabetes Obes Metab. 2023 Aug;25(8 — View Citation

Patti ME, Goldfine AB. The rollercoaster of post-bariatric hypoglycaemia. Lancet Diabetes Endocrinol. 2016 Feb;4(2):94-6. doi: 10.1016/S2213-8587(15)00460-X. Epub 2015 Dec 15. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Time Sensor Glucose <70 mg/dL in the Masked Versus the Unmasked Phase. The primary outcome will be time spent in hypoglycemic glucose range as measured by percent time sensor glucose is <70 mg/dl, comparing the masked versus the unmasked phases. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Primary Percentage of Time Sensor Glucose <60mg/dL in the Masked Versus the Unmasked Phase The primary outcome will be time spent in hypoglycemic glucose range as measured by percent time sensor glucose is <60 mg/dl, comparing the masked versus the unmasked phases. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Primary Percentage of Time Sensor Glucose <54 mg/dL in the Masked Versus the Unmasked Phase The primary outcome will be time spent in hypoglycemic glucose range as measured by percent time sensor glucose is <60 mg/dl, comparing the masked versus the unmasked phases. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Median Sensor Glucose Level During Masked Versus Unmasked Phases of Wear 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Mean Sensor Glucose Level During Masked Versus Unmasked Phases of Wear 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Peak Sensor Glucose Level During Masked Versus Unmasked Period of CGM Wear expressed as median and median standard deviation 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Sensor Glucose Level Range (Highest Sensor Glucose Minus Lowest Sensor Glucose mg/dL) During Masked Versus Unmasked Period of CGM Wear The sensor glucose level range is derived from the difference between the highest sensor glucose levels minus the lowest sensor glucose level (mg/dL). 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Nadir Sensor Glucose Level During Masked Versus Unmasked Period of CGM Wear 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Percent of Time Sensor Glucose 70-180 mg/dL During Period of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Percentage of Time Sensor Glucose Level >180 mg/dL During Period of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Percentage of Time Sensor Glucose Level >250 mg/dL During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Glycemic Variability as Measured by the Standard Deviation of Sensor Glucose Level Data During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Mean Coefficient of Variation of Sensor Glucose Data During Period of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Mean Amplitude of Glycemic Excursion (MAGE) of Sensor Glucose Levels During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary 24 Hour Continuous Overall Net Glycemic Action (CONGA) for Sensor Glucose Data During Periods of CGM Wear, Masked Versus Unmasked Phase CONGA assesses glucose variability within a predetermined time window - 24 hours in this case. Calculation of this parameter is based on the assessment of the differences between glucose values measured at regular time intervals, then on the standard deviation (SD) of these differences 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary 1 Hour Continuous Overall Net Glycemic Action (CONGA) for Sensor Glucose Data During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary 2 Hours, Continuous Overall Net Glycemic Action (CONGA) for Sensor Glucose Data During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary 4 Hours, Continuous Overall Net Glycemic Action (CONGA) for Sensor Glucose Data During Periods of CGM Wear, Masked Versus Unmasked Phase 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Total Number of Hypoglycemic Events During the Masked Versus the Unmasked Phases of CGM Wear, as Defined by a Sensor Glucose <70 mg/dL, for at Least 15 Minutes Hypoglycemic events are defined as having glucose <70 mg/dL for at least 15 minutes, ending when glucose > the threshold. Hypoglycemic event values were normalized by dividing the number of events by the number of days of data. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Total Number of Hypoglycemic Events Defined by a Sensor Glucose <60 mg/dL, for at Lease 15 Minutes, During the Masked Versus Unmasked CGM Phase Hypoglycemic events are defined as having glucose <60 mg/dL for at least 15 minutes, ending when glucose > the threshold. Hypoglycemic event values were normalized by dividing the number of events by the number of days of data. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
Secondary Total Number of Hypoglycemic Events Defined by a Sensor Glucose <54 mg/dL, for at Least 15 Minutes, During the Masked Versus Unmasked CGM Phase Hypoglycemic events are defined as having glucose <54 mg/dL for at least 15 minutes, ending when glucose > the threshold. Hypoglycemic event values were normalized by dividing the number of events by the number of days of data. 28 days for those participants wearing Dexcom G4, and 20 days for participants wearing Dexcom G6.
See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed NCT03667053 - Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children Phase 3
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05597605 - The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT02966275 - Post Bariatric Closed Loop Glucagon Trial N/A
Not yet recruiting NCT02909881 - Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02213003 - Allogeneic Islet Cells Transplanted Onto the Omentum Phase 1/Phase 2
Completed NCT01176656 - Hypoglycemia: Physician and Patient Perspectives N/A
Completed NCT01147276 - Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes Phase 4
Completed NCT00998374 - Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge N/A
Terminated NCT01225159 - Tight Glycaemic Control During Cardiac Surgery N/A
Completed NCT00373854 - Study of How Low Blood Sugar Affects the Way Blood Vessels Work N/A
Completed NCT00285233 - Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes Phase 1/Phase 2
Recruiting NCT05916131 - Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management. N/A
Terminated NCT04026750 - Insulin Tolerance Test Study in Patients With Type 1 Diabetes Phase 1
Completed NCT05133765 - The SMART B Exercise Study :''The SMART Study'' N/A